Epzicom is the brand name for a pharmaceutical treatment for HIV infection. It is a fixed dose combination of lamivudine (3TC, Epivir) and abacavir (ABC, Ziagen). The combination of the two drugs has a stronger effect than either drug alone.
Lamivudine and abacavir are both nucleoside reverse transcriptase inhibitors (NRTI).
It was approved by the FDA on August 2, 2004. It is marketed by GlaxoSmithKline. It is also sold in other countries as Kivexa®